The Philadelphia chromosome is found in more than 95% of patients with chronic myelogenous leukemia. This abnormal chromosome contains 5Ј BCR gene sequences fused to the ABL gene truncated at its 5Ј end (25, 26) . The resulting gene product is a Bcr-Abl protein with greatly elevated protein tyrosine kinase activity (13, 14) . Two forms of the Bcr-Abl protein have previously been described. Depending on the location of the breakpoint within BCR, either a 210-(P210
BCR-ABL
) or 185-kDa (P185
) protein is produced (5) . Both forms of the Bcr-Abl protein are major factors in the induction and maintenance of leukemias, as determined by mouse studies (7, 10) .
Although the mechanism of leukemia induction by these Bcr-Abl oncoproteins is beginning to unfold, the precise oncogenic events are not yet known. It is clear that tyrosine phosphorylation of Abl and Bcr sequences by the activated Abl kinase of Bcr-Abl is a key event in the oncogenic activity of this oncoprotein (1, 23, 24) . We have focused our studies on the role of Bcr in this oncogenic process. Our findings have demonstrated that Bcr is a target for Bcr-Abl (17) . Importantly, sequences within the first exon of Bcr, either within the BcrAbl proteins or P160 BCR , are major sites of Bcr-Abl-catalyzed tyrosine phosphorylation (16) . Moreover, Bcr phosphorylated on tyrosine 177 binds Grb2, a known activator of the Ras pathway (23, 24) . Similarly, other tyrosine kinases can also phosphorylate Bcr at tyrosine 177 (18) .
Bcr is known to possess an intrinsic serine/threonine kinase activity (15, 19, 27) . In this report, we have examined the significance of tyrosine residues within the Bcr amino terminus with regard to their effect on its serine/threonine kinase activity. Our results demonstrate that tyrosine 360 is required for transphosphorylation activity. The phosphorylation of Bcr by Bcr-Abl on tyrosine residues, including Y-360, greatly inhibited the serine/threonine kinase function of Bcr.
MATERIALS AND METHODS
Cells and transient transfection. COS-1 cells were maintained and transfected with various BCR cDNA clones inserted into plasmid vector pSG5, as described previously (17) .
Site-directed mutagenesis. A Transformer site-directed mutagenesis kit (Clontech Labs) was used for generating Y-to-F mutations at residues 177, 283, 276, and 360 by the method of Deng and Nickoloff (8) . Mixtures of mutated and wild-type DNAs were transformed into mutS Escherichia coli, a strain defective in mismatch repair. Plasmid DNA was treated with a restriction enzyme; mutated DNA was resistant to digestion. The presence of mutations was confirmed by DNA sequencing. The mutagenic primers used for mutating Y to F were obtained from Operon Technologies (Alameda, Calif.). For example, the mutant oligonucleotide for Y-276 has the sequence 5Ј CCCCTGGAGTTCCAGCC CTAC 3 (the mutant base is in bold); a similar strategy was used to create Y177F, Y283F, and Y360F. Small fragments from BCR exon 1 were subcloned into pSK or pUC. Mutagenized fragments were sequenced completely to ensure that no other mutations had been introduced. Fragments containing mutations were reinserted into P185 BCR or P185 BCR-ABL cDNAs in vector pSG5. Protein kinase assays. Protein kinase reactions were performed essentially by the method of Liu et al. (16) . Immune complexes were obtained with anti-Bcr (1256-1271) (a rabbit anti-peptide antibody), anti-Bcr(898-911) (a mouse monoclonal antibody), and anti-Abl(51-64) (a mouse monoclonal antibody). For transkinase measurements, Bcr or Bcr-Abl immunobeads were added to reaction buffer containing 10 g of either casein or histone H1. In some experiments, Bcr immune complexes on protein A-Sepharose beads harvested from COS-1 cells overexpressing Bcr (either the wild type or mutants) were mixed with Bcr-Abl immune complexes on protein A-Sepharose beads harvested from COS-1 cells overexpressing Bcr-Abl. Under these conditions, Bcr is transphosphorylated on tyrosine residues. Immune complex beads were washed, and proteins were eluted with sample buffer prior to sodium dodecyl sulfate (SDS) gel electrophoresis. For most of these experiments, one T150 flask of COS-1 cells (about 10 7 ) was used for three kinase reactions. We have found that the autokinase activity of P160 BCR is favored at the expense of the transkinase function at higher concentrations of Bcr in such assays.
Western blotting (immunoblotting). COS-1 cells expressing Bcr proteins were harvested 2 days after transfection and lysed in SDS-2-mercaptoethanol sample buffer prior to electrophoresis on SDS gels. Blots were processed as described by the manufacturer for enhanced chemiluminescence (ECL) with reagents purchased from Amersham (Arlington Heights, Ill.). Anti-Abl 8E9 monoclonal antibody (20) or anti-Bcr(1256-1271) rabbit polyclonal antibodies were used as previously described (4) . Immunoprecipitates were also analyzed by Western blotting as a means of quantitating the amount of Bcr. In this case, P160
BCR was immunoprecipitated with anti-Bcr(1256-1271) by using protein A-Sepharose beads (16) , and the washed beads were treated with SDS sample buffer and separated by gel electrophoresis on SDS-6.5% polyacrylamide gels. After blot-ting and detection of the band by ECL, the band intensities were measured by densitometry.
Quantitative methods. Bands detected by Western blotting on exposed films were quantitated with a Personal Densitometer (Molecular Dynamics, Sunnyvale, Calif.), which gives volume measurements of high precision. Radioactive bands were quantitated with a PhosphorImager (Molecular Dynamics). In addition, the amount of Bcr in a given immunoprecipitate was estimated by adding beads containing Bcr-Abl harvested by immunoprecipitation with anti-Abl(51-64). Our studies show a linear relationship between the level of phosphorylated Bcr and the amount of Bcr-Abl at the levels of immunoprecipitates used in this study.
2-D peptide mapping. Labeled proteins were purified by SDS gel electrophoresis and digested with trypsin or V8 protease (under Glu-favored conditions), as previously described (11, 12) . Peptides were separated on two-dimensional (2-D) thin-layer plates (Kodak Chromatogram; Eastman Kodak Co., Rochester, N.Y.), as previously described (16) .
In vivo orthophosphate labeling of P210 BCR-ABL and P160
BCR
. K562 cells were maintained in medium containing 0.5 mCi of 32 P i per ml for 3 h. Cells were lysed in a modified radioimmunoprecipitation assay buffer designed to inhibit in vitro phosphorylation and prevent phosphatase action (6) . The lysate was immunoprecipitated with anti-Bcr(898-911) mouse monoclonal antibody. Immune complexes were washed with modified radioimmunoprecipitation assay buffer and finally with a high-salt buffer (0.5 M NaCl, 10 mM Tris HCl [pH 7.2], 0.5% Triton X-100, and 100 KIU of aprotinin per ml) to remove nonspecific proteins, as previously described (6) . Bcr-Abl and Bcr proteins were purified by SDS gel electrophoresis and digested with trypsin, as previously described (12) .
Manual sequencing of tryptic peptide spot 1. 32 P-labeled peptides were sequenced by previously published methods (28) . Briefly, each peptide was crosslinked to a filter support (Sequelon AA disks; MilliGen, Burlington, Mass.) by its C-terminal amino acid. After washing with strong acid solutions to remove noncovalently bound radioactivity, the Edman degradation steps were performed. The crucial part of this method is the elution step after each cycle, which is done at 50ЊC in strong acid. This removes the radioactive phosphate more efficiently than do milder procedures. Both the eluate and filter disk are counted for Cerenkov radioactivity to monitor the fate of the 32 P.
RESULTS
Sites of tyrosine phosphorylation of the Bcr moiety within Bcr-Abl. We have previously demonstrated that Bcr transphosphorylated by Bcr-Abl, and Bcr sequences within P210
BCR-ABL

or P185
BCR-ABL undergoing autophosphorylation on tyrosines have virtually identical phosphotyrosine tryptic peptide patterns (16) . These phosphotyrosine-containing tryptic peptides originate from sequences encoded by Bcr exon 1 (16) . We have previously shown that tyrosine 177 is one of these autophosphorylation sites within Bcr-Abl (24) . To identify other possible sites, we compared the 2-D phosphopeptide maps of various mutants of Bcr-Abl in which specific tyrosine residues (Y) had been mutated to phenylalanine (F). Peptides that contain Y residues phosphorylated by Bcr-Abl should be absent from 2-D phosphopeptide maps of Bcr Y3F Bcr-Abl mutants. The expression of mutant Bcr-Abl proteins in COS-1 cells followed by in vitro autophosphorylation showed that a Y3F change at residue 276 gave a wild-type pattern of tryptic peptide spots ( Fig. 1A and B) . This pattern of spots is virtually identical to that found with autophosphorylated P210 harvested from K562 cells (16) . In contrast, Y283F lacked spot 3 ( Fig. 1C ) and Y360F lacked spot 1 (Fig. 1D) . Since no new spots were detected in the F283 and F360 mutants, we conclude that tyrosines 283 and 360 are the only in vitro-phosphorylated residues in tryptic phosphopeptide spots 3 and 1, respectively. These same phosphopeptide spots are present in P160 BCR phosphorylated in trans by Bcr-Abl in vitro (16) .
The position of the phosphotyrosine residue within spot 1 was determined by manual sequencing of 32 P i -labeled spot 1 obtained from autophosphorylated P210
BCR-ABL
. In a typical experiment, a relatively large amount of radioisotope was released after eight cycles of Edman degradation (data not shown). Moreover, spot 1 was not affected by V8 protease treatment under conditions that favor hydrolysis after either a glutamic (E) or an aspartate (D) residue (data not shown). On the basis of the loss of spot 1 in Bcr Y360F, the manual sequence data, the resistance of spot 1 to V8 protease, and its position on 2-D maps obtained under standard conditions (3), we conclude that the sequence of spot 1 is 352-VSPSPTTYR-361.
Bcr tyrosine 360 is phosphorylated in vivo. The experiments discussed above demonstrate that Bcr tyrosine residue 360 is phosphorylated within Bcr-Abl in vitro. To determine whether Bcr-Abl tyrosine 360 is also phosphorylated within cells, we examined P210
BCR-ABL labeled with 32 P i from the chronic myelogenous leukemia cell line K562. The 2-D peptide map of gel-purified P210 shows a number of phosphopeptide spots ( Fig. 2A) . The locations of several spots are similar to those seen on maps of P210 autophosphorylated in vitro, but further studies are necessary to determine their relationship to the in vitro pattern of spots. Of these, spot 1 had the same relative mobility coordinates as those observed for spot 1 in wild-type P210 labeled in the in vitro autophosphorylation assay (Fig.  1A) . Treatment of spot 1 with V8 protease did not change the mobility (Fig. 2B) , whereas all other spots were affected, as seen by a change in mobility (data not shown). Spot 1 from in vitro-labeled P210 was also not affected (Fig. 2C) ; mixing equal amounts of radioactivity from the in vitro-and in vivo-labeled spot 1 produced only one spot (Fig. 2D) . These results demonstrate that Bcr tyrosine 360 is phosphorylated both in vitro and in vivo within P210
BCR-ABL and suggests the functional significance of this residue within the Bcr-Abl protein.
A similar analysis was also performed with 
P160
BCR (Y360F) has reduced transphosphorylation activity, but its autophosphorylation activity is unaffected. Tyrosine phosphorylation of different Bcr exon 1 residues could affect Bcr's enzymatic activity. Moreover, tyrosine residues may be involved in regulating Bcr's serine/threonine kinase activity. To test this, we generated Y3F BCR cDNAs for several residues and these mutant Bcr proteins were examined for serine/threonine kinase activity. Mutant forms of P160
BCR were expressed in COS-1 cells and tested for serine/threonine kinase activities in immune complex kinase assays (Fig. 3A) . Mutant Y360F Bcr P160 was severely inhibited in its ability to transphosphorylate an exogenously added substrate, casein, compared with that of wild-type Bcr (Fig. 3A, lanes 2 and 4) . In contrast, P160 BCR autophosphorylation was not detectably altered by the Y360F mutation (Fig. 3A, lanes 1 and 3) . Western blotting of such extracts showed that the Y360F Bcr mutant protein was stable (Fig. 3B, lane 3) . Using the intensities of the P160 BCR bands (Fig. 3A, lanes 1 and 3) as an indication of the amount of active P160
BCR in the immune complex and the intensities of the casein bands as a measure of transphosphorylation activity, the transphosphorylation activity of the Y360F Bcr mutant was reduced about sevenfold, compared with that of the wild type. Similarly, the Y360F Bcr mutant was also defective in transphosphorylating another exogenous substrate, histone H1 (results not shown).
Because Bcr-Abl contains the moiety of Bcr encoding the serine/threonine kinase domain, we also tested whether P210
BCR-ABL is able to phosphorylate added casein on serine/ threonine. COS-1 cells overexpressing Bcr-Abl were processed by immunoprecipitation with anti-Abl(51-64) monoclonal antibody. In contrast to the C-terminal Bcr antibody, these antiAbl immune complexes contain only trace levels of P160 BCR .
Casein was weakly phosphorylated by P210
BCR-ABL (Fig. 3C , lane 2), whereas casein was strongly phosphorylated by P160 BCR (lane 3). Bcr-Abl-catalyzed phosphorylation of casein must be caused by the Abl tyrosine kinase moiety, because our results also show a deficiency in the serine/threonine kinase activity encoded by Bcr exon 1 of Bcr-Abl (see below).
To determine whether other tyrosine residues in Bcr exon 1 are similarly important to Bcr's serine/threonine kinase activity, we assayed the Y283F mutant Bcr protein (Fig. 4) . Bcr Y283F was not significantly altered in its ability to phosphorylate casein ( Fig. 4A; compare lanes 2 and 4) .
The amounts of Bcr within these immune complexes were quantitated in two ways. First, we used the level of Bcr tyrosine phosphorylation by Bcr-Abl to estimate the amount of Bcr within immune complexes. We had previously established that the amount of phosphorylation of P160
BCR by Bcr-Abl was proportional in a linear fashion in these test tube reactions for the amounts of immune complexes routinely employed in our studies. Thus, by adding a constant amount of active Bcr-Abl complexes to Bcr immune complexes, which results in tyrosine phosphorylation of Bcr by Bcr-Abl (16) (Fig. 4A, lanes 3 , 5, and 7), the level of Bcr (as labeled phosphotyrosine Bcr) in wild-type, Y283F, and Y360F immunoprecipitates could be determined by densitometry analysis of gel bands. Wild-type, Y283F, and Y360F Bcr had intensities of 1,733, 1,261, and 1,050 volume units, respectively. The intensities of the casein bands phosphorylated by these Bcr proteins were 1,673, 2,516, and 25 volume units, respectively. The lack of tyrosine 283 or 360 in mutant Bcr would lower the level of tyrosine phosphorylation to some degree (less than 10%), as judged by the 2-D patterns. Considering this, the amounts of Bcr mutants would be underestimated by about 10%, compared with that of the . K562 cells were labeled with 32 P i for 3 h. Cells were harvested and lysed under conditions that preserve phosphorylated tyrosine residues. Gel-purified P210
BCR-ABL
was digested with trypsin, and peptides were separated on thin-layer plates in our standard 2-D system. The number 1 marks the position of spot 1, which contains phosphotyrosine 360. The origin is marked with a small circle. The radioactive pattern was detected after exposure to X-ray film with enhancing screens. The second method of estimating the amounts of P160 BCR in immune complexes involved the Western blotting of these immune complexes with an anti-Bcr antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.) (Fig. 4B) . In several experiments, no changes in the specific activity of Y283F, compared with that of wild-type Bcr, were found. Quantitation of the intensities of the casein bands (Fig. 4C ) and P160
BCR bands (Fig. 4B ) indicated that Y283F Bcr had specific kinase activity similar to that of wild-type Bcr, but the specific activity of Y360F was reduced by about sixfold. We compared another Bcr mutant (Y177F) with wild-type Bcr by this procedure and again found no change in transkinase activity (Fig. 4B and C) . Thus, these two methods established that the Y360F Bcr protein had significantly reduced ability to phosphorylate an added substrate, compared with that of wild-type Bcr. By using autophosphorylation of the Bcr protein as a measure of its relative amount (Fig. 3A) , the reduction of Bcr's transkinase by the Y360F mutation was about sevenfold, confirming the results obtained by the Western blot method.
Of interest, the presence of wild-type Bcr-Abl did not rescue the transphosphorylation defect of Y360F Bcr. This interpretation is indicated by the failure of Bcr-Abl complexes to restore casein phosphorylation activity when Y360F Bcr immune complexes were mixed with Bcr-Abl immune complexes in the casein phosphorylation reaction mixture (Fig. 4A, lanes 6 and  7) .
Depression of Bcr's serine kinase activity by Bcr-Abl. Because the Y-360 residue is critically involved in Bcr's transphosphorylation activity (Fig. 4) and because of the failure of wild-type Bcr-Abl to rescue the Y360F defect (Fig. 4A, lanes 6  and 7) , we tested the effects of tyrosine phosphorylation of wild-type Bcr on its serine/threonine kinase activity. Bcr-Abl and Bcr immune complexes from separate aliquots of COS-1 cells were mixed to allow Bcr-Abl to tyrosine phosphorylate Bcr. We then assayed the effect of tyrosine phosphorylation of Bcr on its serine/threonine kinase activity (Fig. 5) . Control Bcr P160 (Fig. 5A, lane 2) phosphorylated casein, mostly on serine with low levels of threonine (Fig. 5B, lane 1) . P160
BCR itself was also phosphorylated on serine/threonine residues (Fig. 5D,  lane 1) . However, the addition of Bcr-Abl immune complexes to Bcr immune complexes severely reduced the level of serine/ threonine phosphorylation of casein and caused phosphorylation of casein on tyrosine residues (Fig. 5B, lane 2) .
The addition of Bcr-Abl to Bcr immune complexes also resulted in the transphosphorylation of Bcr on tyrosine residues and simultaneously blocked the serine/threonine autophosphorylation activity of Bcr (Fig. 5C and D) . In these experiments, we measured the phosphoamino acid contents in P160 BCR with and without treatment of Bcr immune complexes with Bcr-Abl. In these studies, Bcr and Bcr-Abl proteins were immunoprecipitated with anti-Bcr(1-16), which directly reacts with Bcr and Bcr-Abl proteins. Autophosphorylated P160 BCR contained phosphoserine/threonine (Fig. 5C, lane 4 , and D, lane 1). In contrast, P160
BCR treated with Bcr-Abl contained predominantly phosphotyrosine, with only low levels of phosphoserine/threonine (Fig. 5C, lane 2, and D, lane 2) . These results demonstrate that in vitro tyrosine phosphorylation of wild-type Bcr severely inhibits its serine/threonine protein kinase, including both autokinase and transkinase activities.
Since the Y-360 residue plays a critical role in Bcr's transki- (Fig. 5C, lane 6) . Phosphoamino acid analysis indicated that tyrosine phosphorylation of Y360F Bcr also blocked its serine/threonine autophosphorylation activity (Fig. 5D, lane 3) . These results suggest that tyrosine residues within Bcr besides Y360 must be phosphorylated by Bcr-Abl in order to inhibit Bcr's autokinase activity. It is of interest to determine whether the Bcr sequences in Bcr-Abl also lack serine/threonine kinase activity. Our previously published results (16) indicate that Bcr-Abl autophosphorylates predominantly on tyrosine residues. To examine this issue in more detail, we measured the kinase activity of tyrosine kinase-defective P210
. The phosphorylation level of P210
BCR-ABL (K1172R) (22) was reduced (Fig. 5C , lane 1), compared with that of either active P210 (lane 2) or active P160
BCR (lanes 1 and 4) . Further studies are required to establish whether this residual activity of P210
BCR-ABL (K1172R) is due to residual serine/threonine autophosphorylation activity or to phosphorylation by Bcr or by kinases that may contaminate these immune complexes.
Tyrosine-phosphorylated Bcr isolated from intact cells is deficient in transkinase activity. To determine whether Bcr harvested from cells coexpressing Bcr-Abl is also deficient in transkinase activity, we isolated Bcr from cells under conditions that favor the retention of phosphotyrosine. In these experiments, we immunoprecipitated Bcr with anti-Bcr(1256-1271) either from extracts of cells lacking Bcr-Abl or from cells that express Bcr-Abl. Under these conditions, Bcr-Abl is coimmunoprecipitated with Bcr because of the presence of BcrAbl-Bcr complexes within the cell (4, 16) . In contrast to previous experiments, we lysed cells in buffer containing 0.4 mM vanadate to block tyrosine phosphatases and therefore maintain the phosphotyrosines within Bcr, as seen in Fig. 2E . Cells coexpressing Bcr with either P210
BCR-ABL or P185
were examined with and without exogenously added substrate (Fig. 6 ). In the absence of Bcr-Abl, Bcr efficiently phosphorylated casein (Fig. 6A, lanes 1 and 2) . Bcr harvested from COS-1 cells expressing P185 BCR-ABL was severely deficient in casein phosphorylation activity (Fig. 6A, lanes 3 and 4) . Quantitative measurements from densitometer scans indicated that P160 BCR harvested from P185
-expressing cells was 25-fold less active for casein phosphorylation than was Bcr from COS-1 cells lacking Bcr-Abl. In a similar experiment, P160 BCR was harvested from P210
BCR-ABL -expressing COS-1 cells. The level of casein phosphorylation by P160
BCR was again significantly reduced (more than sixfold) when Bcr was coexpressed with P210
BCR-ABL (Fig. 6B, lanes 1 and 2) . If tyrosine phosphorylation of Bcr by Bcr-Abl is responsible for the inhibition of Bcr's transkinase activity, then coexpres- sion of a tyrosine kinase-inactive form of P210 BCR-ABL (K1172R) (22) should have little effect on Bcr's transkinase activity. Bcr harvested from such cells had full transkinase activity (Fig. 6B, lanes 3 and 4) . Western blotting established that the expression level of the K1172R mutant was similar to that of wild-type P210
BCR-ABL or P185 BCR-ABL (Fig. 6C ). These results demonstrate that tyrosine phosphorylation of Bcr by Bcr-Abl is the predominant factor in reducing Bcr's serine/ threonine kinase activity.
Bcr-Abl immune complexes harvested in the presence of vanadate had reduced Bcr-Abl autokinase activities (Fig. 6A,  lanes 3 and 4, and 6B, lanes 1 and 2) , despite the rather high levels of expression of both forms of Bcr-Abl (Fig. 6C, lanes 1  and 2) . This low level of in vitro Bcr-Abl autophosphorylation would be expected if the tyrosines in Bcr-Abl were already phosphorylated in vivo in most of the harvested Bcr-Abl protein molecules and were not dephosphorylated during extraction.
DISCUSSION
The results presented here establish that tyrosines 283 and 360 within the first exon of Bcr are phosphorylated by Bcr-Abl in vitro. Importantly, tyrosine 360 of P210
BCR-ABL and tyrosine 360 of P160 BCR were also phosphorylated within live cells, with the latter requiring the presence of active Bcr-Abl. The possible function of tyrosine 283 is not yet known. However, we found that tyrosine residue 360 of Bcr was very important for serine/threonine kinase activity. We found that a Y360F Bcr mutant had significantly reduced ability to transphosphorylate an exogenously added substrate, such as casein or histone H1. In contrast, the mutation of tyrosine 283 to a phenylalanine did not significantly affect the level of Bcr's transkinase activity; nor did the Y177F mutation significantly alter Bcr's kinase function. Of interest, Bcr autophosphorylation activity was not appreciably affected by any of these mutations.
The mechanism by which Y360F Bcr loses its transkinase activity is unknown. We tried to eliminate the possible role of the Y-360 region in substrate binding by using a Bcr peptide containing Y-360 to block transphosphorylation of casein catalyzed by Bcr. Several experiments showed that the addition of Since Bcr tyrosine 360 is phosphorylated by Bcr-Abl, we examined the serine/threonine kinase activity of tyrosine-phosphorylated Bcr. Wild-type Bcr was dramatically inhibited in its serine/threonine kinase activity by in vitro tyrosine phosphorylation catalyzed by Bcr-Abl. This result confirms the differences in the 2-D mapping patterns of autophosphorylated Bcr and Bcr incubated with Bcr-Abl previously reported (16) . Autophosphorylation of Bcr yields a pattern of tryptic peptides distinct from that of Bcr incubated with active Bcr-Abl in kinase reactions (16) . In this study, Bcr's autophosphorylation activity, as measured by phosphoserine/threonine levels in P160 BCR , was also inhibited sharply (Fig. 5) . It is of interest that the Y3F mutation of tyrosine 360 within Bcr downregulates its transkinase activity but does not affect its autokinase activity. In contrast, tyrosine phosphorylation of Bcr (including Y-360) inhibits both auto-and transkinase activities. The reason for the more dramatic effect of tyrosine phosphorylation on Bcr is not yet known. However, it seems likely that extensive Bcr tyrosine phosphorylation causes drastic confirmational changes in Bcr, resulting in the loss of its kinase activities (both auto-and transkinase). It should, however, be emphasized that the fusion of Bcr exon 1 to Abl sequences also downregulated Bcr's kinase activity (Fig. 5C , lane 1), possibly by inducing similar or other types of structural changes. This latter possibility is strengthened by our observation that an inactive Bcr-Abl tyrosine kinase mutant (K1172R) had reduced kinase activity in vitro (Fig. 6B, lane 3) .
In agreement with in vitro tyrosine phosphorylation effects on Bcr, harvesting Bcr from cells expressing functional Bcr-Abl proteins under conditions that favor the retention of phosphotyrosines also inhibited Bcr's transkinase activity toward casein. In contrast, Bcr harvested from cells expressing a tyrosine kinase-deficient mutant of P210 BCR-ABL (K1172R) was not affected. These results indicate that tyrosine phosphorylation of Bcr by Bcr-Abl inhibits Bcr's serine/threonine kinase activity. This inhibition is due at least in part to phosphorylation of Bcr tyrosine 360, as we found that the replacement of tyrosine 360 with phenylalanine caused a dramatic reduction in Bcr transkinase activity while replacing either tyrosine 177 or 283 with phenylalanine had little effect on Bcr's kinase activity. However, the fact that tyrosine phosphorylation interferes with both the auto-and transkinase activities of Bcr indicates that one or more tyrosines in addition to Y-360 is involved. The phosphorylation of multiple tyrosines within the first exon of Bcr may cause some generalized change in Bcr's structure, thereby drastically inhibiting the protein kinase function of Bcr, both auto-and transkinase activities.
It is well-known that tyrosine residues play an active role in the catalytic activity of pyruvate kinase (2) . Moreover, tyrosine phosphorylation of the p34 cdc2 protein kinase downregulates its serine/threonine kinase activity (21) . On the basis of our findings and these published reports, we propose that tyrosine 360 of Bcr plays a crucial role in regulating Bcr's kinase catalytic mechanism. This role may involve facilitating the transfer of the gamma phosphate of ATP to the exogenous substrate. In contrast, tyrosine 360 does not seem to play a role in Bcr's autophosphorylation activity. We propose that a second tyrosine residue within Bcr, when tyrosine phosphorylated, induces inhibition of Bcr's autophosphorylation function.
The inhibition of Bcr's serine/threonine kinase activity by Bcr-Abl-catalyzed phosphorylation of Bcr tyrosine 360 is consistent with the effects of the Y360F mutation. These observed effects argue that the hydroxyl group of tyrosine 360 is crucial for Bcr's transkinase activity. Thus, either the removal of this hydroxyl group by substituting phenylalanine for tyrosine at residue 360 or phosphorylation of this hydroxyl group (catalyzed by the Abl kinase domain) achieves the same result, that is, blocking Bcr's ability to phosphorylate substrates.
These results indicate that Bcr-Abl's effects on Bcr sequences within Bcr-Abl and Bcr are more complicated than previously thought. Phosphorylation of tyrosine 177 within Bcr is known to bind Grb2/Sos and activate the Ras pathway (9, 23, 24) . Our findings in this report indicate that tyrosine phosphorylation of Bcr sequences by the activated Abl kinase of Bcr-Abl blocks its serine/threonine kinase activity, both auto-and transphosphorylation activities. It will be of obvious interest to elucidate the effects of the impairment of Bcr kinase activity on Bcr-Abl-caused leukemias.
